Evidence map›Paper›PMID 33986194›Full record

ArticleJCI insight2021

Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection.

Xiaomo Li, Sijia Yi, Débora B Scariot, Santiago J Martinez, Ben A Falk, Cheryl L Olson, Patricia S Romano, Evan A Scott, David M Engman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Nanomedicines against Chagas disease: a critical review.Beilstein journal of nanotechnology · 2024
    Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Xiaomo LiDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Sijia YiDepartment of Biomedical Engineering, Chemistry of Life Processes Institute, and Simpson Querrey Institute, Northwestern University, Evanston and Chicago, Illinois, USA.
Débora B ScariotDepartment of Biomedical Engineering, Chemistry of Life Processes Institute, and Simpson Querrey Institute, Northwestern University, Evanston and Chicago, Illinois, USA.
Santiago J MartinezDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Ben A FalkDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Cheryl L OlsonDepartment of Pathology, Northwestern University, Chicago, Illinois, USA.
Patricia S RomanoInstitute of Histology and Embryology, "Dr. Mario H. Burgos", IHEM-CONICET, National University of Cuyo, Mendoza, Argentina.
Evan A ScottDepartment of Biomedical Engineering, Chemistry of Life Processes Institute, and Simpson Querrey Institute, Northwestern University, Evanston and Chicago, Illinois, USA.
David M EngmanDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Northwestern University · USCedars-Sinai Medical Center · USUniversidad Nacional de Cuyo · AR

Funding

Development of combination immunotherapies for atherosclerotic inflammationDP2HL132390 · NHLBI · NORTHWESTERN UNIVERSITY · PI SCOTT, EVAN ALEXANDER · 2015 to 2015
$2.3M
Development and characterization of a nanocarrier for enhanced delivery of benznidazole during acute and chronic T. cruzi infectionR21AI144529 · NIAID · NORTHWESTERN UNIVERSITY · PI SCOTT, EVAN ALEXANDER · 2019 to 2020
$517k
NHLBI NIH HHS DP2 HL132390NIAID NIH HHS R21 AI144529
6 · The paper itself

Abstract

Chagas disease is caused by infection with the protozoan parasite Trypanosoma cruzi (T. cruzi), an intracellular pathogen that causes significant morbidity and death among millions in the Americas from Canada to Argentina. Current therapy involves oral administration of the nitroimidazole benznidazole (BNZ), which has serious side effects that often necessitate cessation of treatment. To both avoid off-target side effects and reduce the necessary dosage of BNZ, we packaged the drug within poly(ethylene glycol)-block-poly(propylene sulfide) polymersomes (BNZ-PSs). We show that these vesicular nanocarriers enhanced intracellular delivery to phagocytic cells and tested this formulation in a mouse model of T. cruzi infection. BNZ-PS is not only nontoxic but also significantly more potent than free BNZ, effectively reducing parasitemia, intracellular infection, and tissue parasitosis at a 466-fold lower dose of BNZ. We conclude that BNZ-PS was superior to BNZ for treatment of T. cruzi infection in mice and that further modifications of this nanocarrier formulation could lead to a wide range of custom controlled delivery applications for improved treatment of Chagas disease in humans.

Indexed as

Nanoparticle Drug Delivery SystemAnimalsChagas DiseaseDisease Models, AnimalDose-Response Relationship, DrugDrug CarriersMiceNitroimidazolesPhagocytesPolyethylene GlycolsSulfidesTrypanocidal AgentsTrypanosoma cruzibenzonidazoleDrug CarriersNanoparticle Drug Delivery SystemNitroimidazolesPolyethylene Glycolspoly(ethylene glycol)-stabilized poly(propylene sulfide)SulfidesTrypanocidal AgentsDrug therapyMicrobiologyParasitology

Identifiers

PMID33986194
PMCPMC8262286
OpenAlexW3161491831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.